Santen Pharmaceutical Co (Santen Pharmaceutical Co) 3-Year EBITDA Growth Rate : -36.00% (As of Dec. 2023)

View and export this data going back to 2010. Start your Free Trial

What is Santen Pharmaceutical Co 3-Year EBITDA Growth Rate?

Santen Pharmaceutical Co's EBITDA per Share for the three months ended in Dec. 2023 was $0.29.

During the past 12 months, Santen Pharmaceutical Co's average EBITDA Per Share Growth Rate was 271.30% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was -36.00% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was -18.60% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was -2.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Santen Pharmaceutical Co was 47.00% per year. The lowest was -36.00% per year. And the median was 4.50% per year.

Competitive Comparison of Santen Pharmaceutical Co's 3-Year EBITDA Growth Rate

For the Drug Manufacturers - General subindustry, Santen Pharmaceutical Co's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Santen Pharmaceutical Co's 3-Year EBITDA Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Santen Pharmaceutical Co's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Santen Pharmaceutical Co's 3-Year EBITDA Growth Rate falls into.

Santen Pharmaceutical Co 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Santen Pharmaceutical Co (OTCPK:SNPHY) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Santen Pharmaceutical Co 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Santen Pharmaceutical Co's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Santen Pharmaceutical Co (Santen Pharmaceutical Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Santen Pharmaceutical Co Ltd (OTCPK:SNPHY) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

SNPHF:USA 4536:Japan SZD:Germany

Address

Grand Front Osaka Tower A, 4-20 Ofuka-cho, Kita-ku, Osaka, JPN, 530-8552

Website

http://www.santen.co.jp

Santen Pharmaceutical Co Ltd is a drug manufacturing company that focuses on ophthalmic products. The company reports two primary operating segments: prescription ophthalmic pharmaceuticals and other. The pharmaceuticals segment includes over-the-counter pharmaceuticals, while the other segment includes medical devices. The vast majority of Santen's revenue is derived from its prescription ophthalmic pharmaceuticals segment, which manufactures and distributes prescription and OTC pharmaceuticals. Most of Santen's sales are generated in Japan, followed by other Asian countries.

Santen Pharmaceutical Co (Santen Pharmaceutical Co) Headlines

From GuruFocus

Matthews Japan Fund Comments on Santen Pharmaceutical

By Sydnee Gatewood Sydnee Gatewood • 04-23-2020

Matthews Japan Fund 1st-Quarter Commentary

By Sydnee Gatewood Sydnee Gatewood • 04-23-2020